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Background/aim: The GSTP1 and RASSF1A methylations that were considered as prostate cancer-specific molecular biomarkers have
been extensively reported in Western/American patients with prostate cancer but are rarely reported in Southeast Asian patients. In the
present study, the methylation status of the GSTP1 and RASSF1A promoters was evaluated in prostate cancer (PCa) and benign prostate
hyperplasia (BPH) tissues from Vietnamese men.
Materials and methods: The accuracy of methylation-specific polymerase chain reaction (MSP) was validated to analyze the
methylation pattern of GSTP1 and RASSF1A in 59 PCa and 37 BPH patients, respectively. The methylation status was confirmed by the
sequencing of cloned MSP products. The association between methylation status and the clinical and pathological parameters of tumors
was statistically analyzed.
Results: The methylation of GSTP1 and RASSF1A was detected in 39/59 and 19/59 PCa patients and in 4/37 and 10/37 BPH patients,
respectively. The methylation frequency of GSTP1 was significantly associated with PCa (P < 0.01). The RASSF1A methylation frequency
(32.2%) observed in the study was lower relative to that detected in other populations.
Conclusions: GSTP1 and RASSF1A methylation was accurately detected using the validated MSP method and can be used as a biomarker
to diagnose prostate cancer.
Key words: GSTP1, methylation-specific polymerase chain reaction, RASSF1A

1. Introduction
Prostate cancer (PCa) is the second most frequently
diagnosed cancer and the sixth leading cause of death in
males with cancer worldwide (1). The most current method
for diagnosis for PCa is prostate-specific antigen (PSA)
assays (2). The wide utilization of PSA tests has reduced
the death rates of PCa but it has been associated with a
high risk of overdiagnosis and overtreatment (3). Up to
60% of PSA-detected prostate cancer was overdiagnosed
(4). This disadvantage leads to trouble for healthy men and
is expensive for patients with benign prostate hyperplasia
(BPH) because PSA is a prostate-specific marker only (5).
Thus, the development of additional biomarkers with high
sensitivity and specificity for early detection of prostate
cancer is vitally necessary.
Aberrant methylation of deoxycytidine nucleotides
distributed on CpG islands in promoter sequences is
considered as the earliest somatic genome change in
cancer; thus, it is a promising marker for cancer diagnosis
* Correspondence: vothithuonglan@hus.edu.vn
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(6). In prostate cancer, aberrant DNA methylation
frequently occurs at GSTP1 (glutathione S-transferase P1)
and RASSF1A (RAS association domain family member
1) genes (7,8). GSTP1 protects cells from DNA damage
and contributes to cancer initiation (9). The metaanalysis
of GSTP1 methylation in prostate cancer confirmed
that GSTP1 methylation is a cancer-specific molecular
biomarker for diagnosing prostate cancer with a sensitivity
of 82% and a specificity of 95% (10). The sensitivity and
specificity of GSTP1 methylation status in discriminating
between PCa and BPH reached 85.5% and 100%,
respectively (11). The measurement of GSTP1 promoter
methylation in body fluids showed an excellent specificity,
which was much higher than that of PSA for prostate
cancer diagnosis (12). In addition to GSTP1, RASSF1A is
a tumor suppressor involved in DNA repair and apoptotic
effects (13). Similar to GSTP1, the metaanalysis indicated
that RASSF1A methylation was a potential biomarker
in PCa diagnosis and therapy (14). Aberrant promoter
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methylation of RASSF1A has been frequently detected
(>70%) in prostate cancer, while it was rarely detected in
normal tissues (15). Additionally, RASSF1A is often used in
combination with GSTP1 in making a panel of methylation
markers to improve sensitivity and specificity of prostate
cancer detection (16). Currently, the methylation status of
GSTP1 and RASSF1A is being examined in clinical trials
as a promising diagnostic marker of prostate carcinoma
(15,17).
The highest incidence rates of prostate cancer are in
developed countries and the lowest ones are in developing
countries (1). In prostate cancer, DNA methylation
of individual genes is also highly divergent between
populations (18). DNA methylation in the promoters of
GSTP1 and RASSF1A has extensively been reported in
prostate cancer patients in Europe and the United States,
but it was rarely reported in patients in Southeast Asian
countries. In the present study, we used methylationspecific polymerase chain reaction (MSP) to investigate
DNA methylation status of GSTP1 and RASSF1A in benign
prostatic hyperplasia and cancerous prostate tissues from
Vietnamese patients. Through assessing the methylation
status of these two epigenetic markers, the goal of our study
was to evaluate their potential as diagnosis biomarkers of
prostate cancer in Vietnamese men.

2. Materials and methods
2.1. Prostate tissue samples
Ninety-six formalin-fixed, paraffin-embedded radical
prostatectomy patient specimens, including 59 specimens
of primary PCa and 37 specimens of BPH, were collected
during 2011 and 2012 at the Department of Pathology
of National Cancer Hospital K in Hanoi, the largest
cancer hospital in Vietnam. The blocks with more than
70% cancerous tissue were selected after histological
examination. Clinicopathological characteristics of the
patients were obtained from surgical and pathological
records. Each tumor was graded according to the Gleason
grading system. Informed consent was obtained from the
patients via a written form and the study was approved by
the guidelines of a local ethics committee in Vietnam.
2.2. Genomic DNA extraction and bisulfite modification
Genomic DNA was extracted using a QIAamp DNA FFPE
Tissue Kit (QIAGEN) for formalin-fixed paraffin embedded
specimens and then treated with sodium bisulfite using an
EpiTect Bisulfite Kit (QIAGEN). During the modification,
the unmethylated cytosines of the genomic DNA were
converted to uracils, but the methylated cytosines remained
unchanged (19). Polymerase chain reaction (PCR) that
used globin F/R primers for the native DNA and Un-globin
F, R, and R1 for treated DNA (Table 1) was performed to

Table 1. MSP primers for analysis of β-globin, GSTP1, and RASSF1A methylation. The lower letters “t” and “a” indicate the unmethylated
cytosines that were changed to “t” in the forward primers and to “a” in the reversed primers.
Gene

β-globin
U01317.1

GSTP1
NC_000011.9

RASSF1A
NG_023270.1

Primers

Sequence (5’–3’)

Globin F

CAACTTCATCCACGTTCACC

Globin R

GAAGAGCCAAGGACAGGTAC

Un-globin F

AGAAGAGttAAGGAtAGGTAtGGtTGT

Un-globin R

CTTaCCCCACAaaaCAaTAACaaCAaA

Un-globin F

AGAAGAGttAAGGAtAGGTAtGGtTGT

Un-globin R1

ACTTCTCCTCAaaAaTCAaATaCACCA

GS Me-F1

ttCGGttAGtTGCGCGGCGAtTtC

GS Me-R

CGaCGAAACTCCAaCGAAaaC

GS Me-F2

ttCGGGGTGtAGCGGtCGtC

GS Me-R

CGaCGAAACTCCAaCGAAaaC

GS Un-F1

AGtTGtGtGGtGAtTttGGGGAtA

GS Un-R

CCAaCaAAaaCCTCaCaaCCTCCa

GS Un-F2

GAtGtttGGGGTGtAGtGGttGttG

GS Un-R

CCAaCaAAaaCCTCaCaaCCTCCa

RM F

GGtTtTGCGAGAGCGCGtttA

RM R

CaaCGCTAaCAAaCGCGaaCCGa

UM240 F

GGGGtTtTGtGAGAGtGtGtttAG

UM241 R

TaaaCaCTAaCAAaCaCaaaCCaaaC

Un F

GAGAGtGtGtttAGttttGttT

Un R

CCACAaaaCaaaCCCCaACTT

Size (bp)

MSP conditions

References

268

94 °C 5 min, 40 cycles of (94 °C 30 s, 62
°C 10 s, 72 °C 10 s), 72 °C 5 min

(20)

Round 1: 250

94 °C 5 min, 40 cycles of (94 °C 30 s, 62
°C 10 s, 72 °C 10 s), 72 °C 5 min

Present study

Round 2: 224

94 °C 5 min, 40 cycles of (94 °C 30 s, 65
°C 10 s, 72 °C 10 s), 72 °C 5 min

Present study

Round 1: 210

94 °C 5 min, 40 cycles of (94 °C 30 s, 65
°C 20 s, 72 °C 20 s), 72 °C 5 min

(21,22)

Round 2: 155

94 °C 5 min, 40 cycles of (94 °C 30 s, 65
°C 20 s, 72 °C 15 s), 72 °C 5 min

Round 1: 194

94 °C 5 min, 40 cycles of (94 °C 30 s, 62
°C 20 s, 72 °C 20 s), 72 °C 5 min

Present study

Round 2: 149

94 °C 5 min, 40 cycles of (94 °C 30 s, 66
°C 10 s, 72 °C 15 s), 72 °C 5 min

Present study

170

94 °C 5 min, 40 cycles of (94 °C 30 s, 68
°C 20 s, 72 °C 20 s), 72 °C 5 min

Present study

Round 1: 175

94 °C 5 min, 40 cycles of (94 °C 30 s, 60
°C 20 s, 72 °C 10 s), 72 °C 5 min

(26)

Round 2: 135

94 °C 5 min, 40 cycles of (94 °C 30 s, 65
°C 10 s, 72 °C 10 s), 72 °C 5 min

Present study

(23,24,25)
Present study
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determine the efficiency of bisulfite conversion, and PCR
that used MSP primers for the native DNA was performed to
confirm the primer’s specificity only to methylated targets.
2.3. Methylation-specific PCR (MSP)
The methylation status of GSTP1 and RASSF1A was
evaluated by using MSP for amplification of bisulfitetreated DNA with primers that distinguish methylated
(M) from unmethylated (U) DNAs. Based on the primer
designing tool for the MSP method (http://www.urogene.
org/methprimer/index1.html), the primers for GSTP1 and
RASSF1A were designed, and some of these primers were
used in combination with the published ones (20–26).
The primer sequences and amplicon lengths are shown in
Table 1. Bisulfite-treated DNAs were subjected to single or
nested PCR based on particular targeted genes. The PCR
products were then subjected to electrophoresis on 12%
acrylamide gel. All the PCR reactions were replicated at
least three times.
DNA that was extracted from the lymphocytes of
the healthy volunteers and then treated with bisulfite
was used as a positive control for GSTP1 and RASSF1A
unmethylation. DNA that was extracted from the PC3 cell
line and then treated with bisulfite was used as a positive
control for GSTP1 and RASSF1A methylation (27). Water
without a DNA template was included in each PCR reaction
as a control for any contamination. The methylation status
was confirmed by sequencing the cloned MSP products for
a subset of samples from each assay.
2.4. Statistical analysis
Associations between clinicopathological characteristics
and individual promoter methylation status were examined
by using the chi-square test (SPSS Inc., Chicago, IL,
USA). For all statistical analyses, P ≤ 0.05 was considered
significant.

3. Results
The population in this study consisted of 59 patients
with PCa and 37 patients with BPH, all of whom
underwent radical prostatectomy. The clinicopathologic
characteristics of all 96 patients are shown in Table 2. The
median age of the cases was 71.65 years (range: 42–91),
and most of the cases had tumors with Gleason grade IV
or V (41/59 PCa, 69.4%).
3.1. Verification of the specificity of MSP primers
Validating the precision of the MSP primers specific
only to the methylated target has been recommended in
order to avoid false positive results due to coamplification
of incompletely converted sequences (28). Thus, the
bisulfite-untreated DNA and the bisulfite-treated DNA
were separately subjected to MSP with the GSTP1 and
RASSF1A primer sets that were specifically designed for
the methylated targets. Efficient amounts of the DNA
templates were checked by PCR with the globin primer
sets that were designed from the native and unmethylated
DNA targets (Figure 1A). No MSP products corresponding
to the methylated GSTP1 and RASSF1A were amplified
from untreated DNA extracted either from PC-3 cells
or from the lymphocytes. Similarly, no MSP products
corresponding to the methylated targets were amplified
from treated DNA extracted from the lymphocytes, which
was used as the positive control for unmethylated DNA.
The methylated GSTP1 and RASSF1A were detected from
only the treated DNA extracted from PC-3 cells (Figure
1B). The results confirmed the accuracy of the designed
primer sets specific only to the methylated targets. These
primers were subsequently subjected to analysis of the
methylation status of GSTP1 and RASSF1A in prostate
patients.

Table 2. Methylation frequencies of GSTP1 and RASSF1A in the samples of benign hyperplasia (BPH) and prostate cancer (Pca) patients.

Characteristics

Overall,
n = 96

Age (years)
Median
Range

GSTP1

RASSF1A

Un, n (%)

Me, n (%)

71.65
42–91

92

43

Histological type
Pca
BPH

59
37

55 (93.2)
37 (100.0)

39 (66.1)
4 (10.8)

Histological grade (Gleason)
I+II
III
IV+V

5
13
41

5 (100)
10 (76.9)
40 (97.6)

4 (80.0)
10 (76.9)
25 (61.0)

P-value

Un, n (%)

Me, n (%)

94

29

<0.01

58 (98.3)
36 (97.3)

19 (32.2)
10 (27.0)

0.59

0.45

5 (100)
12 (92.3)
41 (100)

1 (20.0)
5 (38.5)
13 (41.5)

0.75

P-value: statistical analysis of the associations between clinicopathological characteristics and methylation status.
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Figure 1. A–B) The efficiency of bisulfite conversion of genomic DNA that was extracted from PC3 cell line (A) and from the lymphocytes
(L) of the healthy volunteers (B). A band of 268 bp amplified from only the untreated DNAs (UT) by globin primers and a band of 244 bp
amplified from only the treated DNAs (BT) by nested Un globin primer sets. C–D) Specificity of the GSTP1 and RASSF1A primer sets to
only the methylated DNAs. A band of 155 bp and 170 bp amplified from only the treated genomic DNAs by the GSTP1 (C) and RASSF1A
(D) primer sets specifically designed for methylated sequences. M: 100-bp DNA ladder. (–): Negative control without DNA template.

3.2. Methylation status of GSTP1 and RASSF1A in PCa
and BPH tissues
The genomic DNAs extracted from 59 PCa and 37 BPH
specimens were treated with bisulfite and subjected directly
to MSP. Representative results of the MSP products for
methylation status of GSTP1 and RASSF1A are shown in
Figures 2 and 3, respectively. Three patterns of M/M, M/U,
and U/U signals of RASSF1A were observed in both PCa
and BPH cases, but these patterns of GSTP1 were observed
in cases of PCa only (Table 3). Biallelic unmethylation (U/U)

and monoallelic methylation (M/U) signals of GSTP1 were
detected from BPH. Monoallelic M/M and biallelic M/U
were count as the methylated status. MSP analysis revealed
that the number of the methylated GSTP1 and RASSF1A
was 39/59 (66.1%) and 19/59 (32.2%) patients with PCa,
respectively (Table 2). MSP analysis also revealed that the
methylation of GSTP1 and RASSF1A was detected in 4/37
(10.8%) and 10/37 (27%) patients with BPH, respectively.
Forty-three out of 59 PCa (72.9%) samples showed
methylation status of one or two genes.

B2

Figure 2. Representative results of the methylation analysis of GSTP1 in the prostate cancer (P1–P10) and benign hyperplasia (B1–B12)
samples. The PCR products in lanes Me and Un indicate the presence of methylated (155 bp) and unmethylated (149 bp)GSTP1. L:
lymphocytes of the healthy volunteers. PC3: prostate cell line. (–): Negative control without DNA template. M: 100-bp DNA ladder.
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Figure 3. Representative results of the methylation analysis of RASSF1A in the prostate cancer (P1–P10) and the benign hyperplasia
(B1–B12) samples. The PCR products in lanes Me and Un indicate the presence of methylated (170 bp) and unmethylated (135 bp)
RASSF1A. L: lymphocytes of the healthy volunteers. PC3: prostate cell line. (–): Negative control without DNA template. M: 100-bp
DNA ladder.
Table 3. Status and frequency of methylation of GSTP1 and RASSF1A in PCa and BPH. Three patterns of M/M, M/U, and U/U.

Genes

PCa

BPH

GSTP1

RASSF1A

GSTP1

RASSF1A

M/M

4

1

0

1

M/U

35

18

4

9

U/U

20

40

33

27

Methylation ratio

39/59 (66.1%)

19/59 (32.2%)

4/37 (10.8%)

10/37 (27%)

The DNA methylation frequencies and clinical
characteristics corresponding to surgical and pathological
records of the cases were compared. There was a significant
difference in the methylation rate between PCa and
BPH for only GSTP1 (P < 0.01) (Table 2). No significant
differences in the methylation frequencies of GSTP1 and
RASSF1A were observed in terms of age and histological
grade (Gleason) of the PCa patients (Table 2).
The methylation and unmethylation of GSTP1 and
RASSF1A were confirmed by cloning and sequencing
MSP products that were amplified from the treated DNAs
extracted from the prostate cancer samples (Figure 4). The
nucleotide sequences showed that all cytosine residues
were converted to thymidines in the GSTP1 and RASSF1A
unmethylated products, and that all cytosines in the CpG
sites remained as cytosines and the cytosines that were
not in the CpG sites were converted to thymidines in the
GSTP1 and RASSF1A methylated products.
4. Discussion
Among several DNA methylation markers associated
with prostate cancer, GSTP1 and RASSF1A methylations
captured the most interest because they were strongly
associated with and considered as specific molecular
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biomarkers of prostate cancer (5). Highly significant
GSTP1 and RASSF1A methylation rates have been
extensively reported from tissue biopsies and body fluids
(plasma, serum, whole blood, urine, semen) from patients
with prostate cancer (12,24,28) This evidence makes
them the most promising commercial DNA methylation
markers for early detection of this cancer (5).
DNA methylation profiles of thousands of genes
or of a particular gene can be quantitatively assessed by
technological approaches such as DNA microarrays or
methylation-sensitive high-resolution melting (MSHRM), which may not be accessible to many institutions
in developing countries (29,30). The MSP method was
chosen in the present study because of its sensitivity,
specificity, and suitability in most moderately equipped
laboratories (31). However, false positive results due to
MSP primers unspecific to the methylated target have
been reported (28). Thus, the standard controls were
set up to test the accuracy of the primers specific to the
methylated GSTP1 and RASSF1A through PCR, in which
MSP products were amplified neither from the native
DNA that was extracted from the lymphocytes or from
PC3 cells, nor from the bisulfite-treated DNA that was
extracted from the lymphocytes (Figure 1). This finding

VO et al. / Turk J Med Sci

Figure 4. The native sequences of GSTP1 (NC_000011.9) and RASSF1A (NG_023270.1) in comparison with their methylated (upper)
and unmethylated (lower) sequences. Cytosines in the CpG sites (underlined) remained cytosines in the methylated sequences but
they converted to thymidines in the unmethylated ones. All cytosines alone were converted to thymidines in both the methylated and
unmethylated sequences.

confirmed that the unmethylated targets, as well as a trace
of incompletely treated DNA, had not interfered with the
MSP results; thus, false positive results were avoided.
The MSP result for one gene is dependent on the
analyzed sequence of the 5’ region; thus, the same nucleotide
regions of GSTP1 and RASSF1A promoters that have been
previously analyzed by the MSP method were also chosen
in the present study (21–24,26,28). GSTP1 and RASSF1A
methylation status of malignant (PCa) and benign (BPH)
prostate lesions was elucidated by performing the MSP
with the validated primer sets. In a total of 96 patients,
39/59 (66.1%) and 19/59 (32.2%) of PCa cases and 4/37
(10.8%) and 10/37 (27%) of BPH cases were methylated
at the GSTP1 and RASSF1A promoters, respectively. A
significant difference in GSTP1 methylation rates was
only observed between PCa and BPH (P < 0.01) (Table 3).
This result was consistent with previous reports in which
PCa was sensitively and specifically discriminated from
BPH based on GSTP1 methylation (11,21). The GSTP1

methylation frequency of 66.1% detected in the present
study was comparable to that detected in different racial
groups. Indeed, the GSTP1 methylation frequency in the
same nucleotide region that was analyzed in this study was
90.9%, 73.2%, and 58% from American, Korean, and Indian
patients with PCa, respectively (22,33,34). On the contrary,
no significant association was observed between RASSF1A
methylation status and the clinicopathological parameters
from the Vietnamese men who suffered from prostate
lesions. In addition, the RASSF1A methylation frequency of
32.2% observed in this study was relatively lower than that
detected in other populations, although a similar frequency
was found in one other study (34). The methylation
frequency of RASSF1A in Japanese and Pakistan patients,
which was analyzed using the MSP method, was 74.0%
and 100%, respectively (15,35). In a Portuguese population
the methylation frequency of RASSF1A was more than
90% as analyzed by the quantitative MSP method (36).
Alternatively, the lower frequency of RASSF1A methylation
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in this study might be due to the MSP primer’s specificity
that was validated (Figure 1). Indeed, false positive
results gave rise to an increase of 4 and 2 times the DNA
methylation frequency (28).
A similar frequency of RASSF1A methylation in PCa
(32.2%) and in BPH (27%) cases was observed in this
study and in previous reports (25,34). The occurrence of
methylation of RASSF1A in tumor and nontumor tissues
from various cancers suggested that it is an early and
premalignant sign (37). Thus, RASSF1A methylation in
BPH has been considered as a sign of tumor progression.
Indeed, a metaanalysis from 19 published studies on the
association between RASSF1A promoter methylation and
prostate cancer indicated that RASSF1A methylation was
significantly associated with an increased risk of PCa (38).
Currently, the GSTP1 and RASSF1A methylation in
body fluids is extensively studied because of its noninvasive

character and its ability to monitor prostate cancer (24,39).
A high specificity of GSTP1 and RASSF1A methylation
was found in these studies, regardless of methylation
methods (12,14). Thus, the MSP method, which was
supported by previous studies and was standardized in
this study, is advantageous for further analyzing GSTP1
and RASSF1A methylation in body fluid specimens. Our
study emphasized the authentic value of the MSP method
that will allow the use of DNA methylation marker to
quickly progress toward clinical application, especially in
developing countries.
Acknowledgment
This study was ﬁnancially supported by grants KC.04.05/1115 from the Ministry of Science and Technology of
Vietnam.

References
1.

Jamel A, Center MM, DeSantis C, Ward EM. Global patterns
of cancer incidence and mortality rates and trends. Cancer
Epidemiol Biomarkers Prev 2010; 19: 1893–1907.

2.

Venderbos LD, Roobol MJ. PSA-based prostate cancer
screening: the role of active surveillance and informed and
shared decision making. Asian J Androl 2011; 13: 219–224.

3.

Esserman LJ, Thompson IM, Reid B. Over diagnosis and over
treatment in cancer: an opportunity for improvement. JAMA
2013; 310: 797–798.

4.

Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer
Inst 2010; 102: 605–613.

5.

Ahmed H. Promoter methylation in prostate cancer and its
application for the early detection of prostate cancer using
serum and urine samples. Biomark Cancer 2010; 2: 17–33.

6.

Dawson MA, Kouzarides T. Cancer epigenetics: from
mechanism to therapy. Cell 2012; 150:12–27.

7.

Maxwell A, McCudden CR, Wians F, Monte S, Willis MS.
Recent advances in the detection of prostate cancer using
epigenetic markers in commonly collected laboratory samples.
Lab Med 2009; 40: 171–178.

8.

Majumdar S, Buckles E, Estrada J, Koochekpour S. Aberrant
DNA methylation and prostate cancer. Cur Genomics 2011; 12:
486–505.

9.

Lo HW, Stephenson L, Cao X, Milas M, Pollock R, Ali-Osman
F. Identification and functional characterization of the human
glutathione S-transferase P1 gene as a novel transcriptional
target of the p53 tumor suppressor gene. Mol Cancer Res 2008;
6: 843–850.

10.

234

Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI,
Criekinge WV. The epigenetic promise for prostate cancer
diagnosis. Prostate 2012; 72: 1248–1261.

11.

Yoon HY, Kim YW, Kang HW, Kim WT, Yun SJ, Lee SC, Kim
WJ, Kim YJ. DNA methylation of GSTP1 in human prostate
tissues: pyrosequencing analysis. Korean J Urol 2012; 53: 200–
205.

12.

Wu T, Giovannucci E, Welge J, Mallick P, Tang WY, Mho S.
Measurement of GSTP1 promoter methylation in body fluids
may complement PSA screening: a meta-analysis. Br J Cancer
2011; 105: 65–73.

13.

Dammann R, Takahashi T, Pfeifer GP. The CpG island of the
novel tumor suppressor gene RASSF1A is intensely methylated
in primary small cell lung carcinomas. Oncogenes 2001; 20:
3563–3577.

14.

Pan J, Chen J, Zhang B, Chen X, Huang B, Zhuang J, Mo C, Qiu
S. Association between RASSF1A promoter methylation and
prostate cancer: a systematic review and Meta-analysis. PLoS
ONE 2013; 8: e75283.

15.

Kawamoto K, Okino ST, Place RF, Urakami S, Hirata H,
Kikuno N, Kawakami T, Tanaka Y, Pookot D, Chen Z et al.
Epigenetic modifications of RASSF1A gene through chromatin
remodeling in prostate cancer. Clin Cancer Res 2007; 13: 2541–
2548.

16.

Rabiau N, Thiam MO, Satih S, Guy L, Kemeny JL, Boiteux JL,
Fontana L, Bignon YJ, Bernard-Gallon D. Methylation analysis
of BRCA1, RASSF1, GSTP1 and EPHB2 promoters in prostate
biopsies according to different degrees of malignancy. In Vivo
2009; 23: 387–392.

17.

Sunami E, Shinozaki M, Higano CS, Wollman R, Dorff TB,
Tucker ST, Martinez SR, Singer FR, Hoon DSB. Multimarker
circulating DNA assay for assessing blood of prostate cancer
patients. Clin Chem 2009; 55: 559–567.

VO et al. / Turk J Med Sci
18.

Addo BK, Wang S, Chung W, Jelinek J, Patierno SR, Wang BD,
Andrawis R, Lee NH, Apprey V, Issa JP et al. Identification of
differentially methylated genes in normal prostate tissues from
African American and Caucasian men. Clin Cancer Res 2010;
16: 3539–3547.

19.

Clark SJ, Statham A, Stirzaker C, Molloy PL, Frommer M.
DNA methylation: bisulphite modification and analysis. Nat
Protocol 2006; 1: 2355–2364.

20.

Wilcox CB, Baysal BE, Gallion HH, Strange MA, DeLoia JA.
High-resolution methylation analysis of the BRCA1 promoter
in ovarian tumors. Cancer Genet Cytogen 2005; 159: 114–122.

21.

Maruyama R, Toyooka S, Toyooka KO, Virmani AK,
Zochbauer-Muller S, Farinas AJ, Minna JD, McConnell J,
Frenkel EP, Gazdar AF. Aberrant promoter methylation profile
of prostate cancers and its relationship to clinicopathological
features. Clin Cancer Res 2002; 8: 514–519.

22.

Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA,
Nelson WG, De Marzo AM. Hypermethylation of the human
glutathione S-transferase π gene (GSTP1) CpG island is present
in a subset of proliferative inflammatory atrophy lesions but
not in normal or hyperplastic epithelium of the prostate. Am J
Pathol 2003; 163: 923–933.

23.

Esteller M, Corn PG, Drena JM, Gabrielson E, Baylin SB,
Herman JG. Inactivation of glutathione S-transferase P1 gene
by promoter hypermethylation in human neoplasia. Cancer
Res 1998; 58: 4515–4518.

24.

Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG. Prostate
cancer detection by GSTP1 methylation analysis of postbiopsy
urine specimens. Clin Cancer Res 2003; 9: 2673–2677.

25.

Dimitriadis E, Kalogeropoulos T, Velaeti S, Sotiriou S, Vassiliou
E, Fasoulis L, Klapsas V, Synesiou M, Apostolaki A, Trangas
T et al. Study of genetic and epigenetic alterations in urine
samples as diagnostic markers for prostate cancer. Anticancer
Res 2013; 33: 191–197.

26.

Liu L, Yoon JH, Dammann R, Pfeifer GP. Frequent
hypermethylation of the RASSF1A gene in prostate cancer.
Oncogene 2002; 21: 6835–6840.

27.

Vardi A, Bosviel R, Rabiau N, Adjakly M, Satih S, Dechelotte P,
Boiteux J, Fontana L, Bignon YJ, Guy L et al. Soy phytoestrogens
modify DNA methylation of GSTP1, RASSF1A, EPH2 and
BRCA1 promoter in prostate cancer cells. In Vivo 2010; 24:
393–400.

28.

Lan TV, Ha TN, Uyen QN, Duong TN, Huong TN, Thuan BT,
Duong PA, To VT. Standardization of the methylation-specific
PCR method for analysing BRCA1 and ER methylation. Mol
Med Reports 2014; 9: 1844–1850.

29.

Wojdacz TK, Dobrovic A. Methylation-sensitive high
resolution melting (MS-HRM): a new approach for sensitive
and high-throughput assessment of methylation. Nucl Acids
Res 2007; 35: e41.

30.

Houshdaran S, Hawley S, Palmer C, Campan M, Olsen MN,
Ventura AP, Knudsen BS, Drescher CW, Urban ND, Brown PO
et al. DNA methylation profiles of ovarian epithelial carcinoma
tumors and cell lines. PLoS ONE 2010; 5: e9359.

31.

Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB.
Methylation-specific PCR: a novel PCR assay for methylation
status of CpG islands. P Natl Acad Sci USA 1996; 93: 9821–
9826.

32.

Kristensen LS, Hansen L. PCR-based methods for detecting
single-locus DNA methylation biomarkers in cancer
diagnostics, prognostics, and response to treatment. Clin
Chem 2009; 55: 1471–1483.

33.

Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, Cho YM,
Kim D, Kang GH. Hypermethylation of CpG island loci
and hypomethylation of LINE-1 and Alu repeats in prostate
adenocarcinoma and their relationship to clinicopathological
features. J Pathol 2007; 211: 269–277.

34.

Syeed N, Sameer AS, Hamid A, Shah ZA, Afroze D, Rasool
R, Siddiqi MA. Promoter methylation profile of GSTP1 and
RASSF1A in benign hyperplasia and metastatic prostate cancer
patients in a Kashmiri population. Mol Med Rep 2010; 3: 883–
887.

35.

Yaqinuddin A, Qureshi SA, Pervez S, Bashir MU, Nazir R,
Abbas F. Frequent DNA hypermethylation at the RASSF1A
and APC gene loci in prostate cancer patients of Pakistani
origin. ISRN Urology 2013; 2013: 627249.

36.

Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR,
Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D. A
quantitative promoter methylation profile of prostate cancer.
Clin Cancer Res 2004; 10: 8472–8478.

37.

Dammann R, Schagdarsurengin U, Seidel C, Strunnikova
M, Rastetter M, Baier K, Pfeifer GP. The tumor suppressor
RASSF1A in human carcinogenesis: an update. Histol
Histopathol 2005; 20: 645–653.

38.

Ge YZ, Xu LW, Jia RP, Xu Z, Feng YM, Wu R, Yu P, Zhao Y, Gui
ZL, Tan SJ et al. The association between RASSF1A promoter
methylation and prostate cancer: evidence from 19 published
studies. Tumor Biol 2014; 35: 3881–3890.

39.

Bastian PJ, Palapattu GS, Yegnasubramanian S, Rogers CG, Lin
X, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson
WG. CpG island hypermethylation profile in the serum of men
with clinically localized and hormone refractory metastatic
prostate cancer. J Urol 2008; 179: 529–535.

235

